Latest Prasugrel Stories
A study has found that the anti-clotting medication prasugrel reduced cardiovascular events among patients who present with an acute coronary syndrome and are managed medically after an angiogram is performed to determine coronary anatomy.
Standard antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) consists of a dual antiplatelet therapy with aspirin and an ADP receptor inhibitor such as clopidogrel.
The first trial to study the effect of platelet inhibition in patients with acute coronary syndromes managed medically without revascularization has found no significant difference between prasugrel and clopidogrel in the prevention of death, myocardial infarction or stroke.
The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs – prasugrel and clopidogrel – in preventing the first occurrence of death, heart attack or stroke.
Researchers report no significant difference in high versus low dose aspirin in preventing recurring cardiovascular events.
New research finds ongoing treatment with ticagrelor safe and effective in patients with acute coronary syndrome.